about
Experimental oral candidiasis in animal models.Immunization with the Candida albicans membrane fraction and in combination with fluconazole protects against systemic fungal infectionsCD4(+)-T-Cell-mediated resistance to systemic murine candidiasis induced by a membrane fraction of Candida albicans.Early resistance of interleukin-10 knockout mice to acute systemic candidiasis.Candidaemia and cancer: patients are not all the same.Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasisPostmortem candidaemia: marker of disseminated disease.Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei.Amphotericin B or ketoconazole therapy of fungal infections in neutropenic cancer patients.Gamma interferon is not essential in host defense against disseminated candidiasis in miceDiagnosis of disseminated candidiasis by measurement of urine D-arabinitol/L-arabinitol ratio.Macrophages in resistance to candidiasisHypersplenism due to fungal infection of spleen in a successfully treated patient with Hodgkin's disease.Diagnosing fungal infections in immunocompromised hostsProperties of a rat monoclonal antibody reactive with both the mannan of Candida species and the O-antigen 6,7 polysaccharide of serogroup C1 salmonellaeIncreased susceptibility to lethal Candida infections in burned mice preinfected with Pseudomonas aeruginosa or pretreated with proteolytic enzymesDiagnosis of invasive candidiasis by a dot immunobinding assay for Candida antigen detectionFungal infections of the small and large intestineChemical synthesis, pharmacological characterization, and possible formation in unicellular fungi of 3-hydroxy-anandamide.Comparison of antibody, antigen, and metabolite assays in rat models of systemic and gastrointestinal candidiasis.Risk factors for candidemia in cancer patients: a case-control study.Comparison of antibody, antigen, and metabolite assays for hospitalized patients with disseminated or peripheral candidiasis.Increased incidence of fungemia caused by Candida krusei.Microtiter broth dilution method for yeast susceptibility testing with validation by clinical outcome.Collaborative evaluation of antigen detection by a commercial latex agglutination test and enzyme immunoassay in the diagnosis of invasive candidiasis.Comparison of restriction enzyme analysis and pulsed-field gradient gel electrophoresis as typing systems for Candida albicans.A novel immunocompetent murine model for Candida albicans-promoted oral epithelial dysplasiaImproved immunodiagnosis of human candidiasis by an enzyme-linked immunosorbent assay using a Candida albicans 52-kilodalton metallopeptidase.Liposomes as carriers of antimicrobial agentsComparison of restriction enzyme analysis versus pulsed-field gradient gel electrophoresis as a typing system for Torulopsis glabrata and Candida species other than C. albicans.Diagnosis of invasive candidiasis by detection of mannan antigen by using the avidin-biotin enzyme immunoassay.Effect of inoculum size on detection of Candida growth by the BACTEC 9240 automated blood culture system using aerobic and anaerobic media.Rechargeable anticandidal denture material with sustained release in saliva.
P2860
Q33975696-A3C9722C-EDEB-4CFF-8D51-005A541F1BC7Q33978613-B4210D5D-94F0-497A-B7BC-1BBB16BEE739Q33980697-2885CCEC-C1BD-4C4C-9B3D-DF3033DAFC45Q34000250-94003BAA-7464-4EE3-8DD7-9FE6E505BC52Q34521837-164AB29C-A7C5-419E-A8FA-D712D2A0B2E8Q34529190-E2FF25D9-96DC-481D-AD90-DE3CBE171903Q34907626-9B26DB4E-3B27-4109-BDD7-8B86FD8B96C1Q35347298-672A4727-28DE-4BFE-A0DB-E22D690F7903Q35535361-333568E1-67C9-4ABB-A3F8-79AA9E4078BCQ35546571-1A03660D-9DFF-4419-9D80-3BCB9782BD73Q36537655-CEEE62BA-3E3F-4250-88E1-A2C66941DA1BQ36574240-59D540D3-19E8-4F52-BD0F-2008B01A1008Q36722797-7B212850-1E3D-43AA-8402-E7ABC60BF1CAQ36778861-5AE26161-4D27-4009-B158-15C3E1E4AF00Q36959525-5DBD28C5-6BB8-43CF-8709-F27E6A3BD84DQ37054102-4B7BAD17-56A1-42AF-B628-61BA299FF122Q37065516-708A96DD-E297-4C50-A6E8-92B029AAA096Q37109208-19830BE4-09AA-4763-AA8B-A655FA828398Q37130799-1CF41860-CFCC-402F-A878-79603072350BQ37144728-7C74DCE2-C565-4047-8132-3A717E5A33CDQ37144804-621170E9-0FF7-4437-9246-883EA8ADEC8AQ37182563-3B5C01DA-5414-496E-837C-822D02DF6F10Q37210628-4AF8B8EC-EA32-430B-8690-D3516C469FB0Q37210734-B8CF65EA-BC65-4617-9968-CD1BCB954D49Q37226142-52CEFF7E-2FB0-4D66-8BC1-55F3A99447F7Q37234390-9680806A-D19C-45BD-99C3-F93828AAEC70Q37315206-0A8C6B83-954D-4980-89E2-96A4BF700684Q39508786-FF04BC16-BD8F-4846-B26C-6264D537A26AQ39661451-17A1E9BE-0B7F-4189-91AC-6320A7F2B8EBQ40188406-3CA336EB-B92A-44A5-B850-DF385B627667Q40214015-8EAB1CBA-CCF9-48EC-8FDA-C34762DD8C27Q40771165-FB35AD85-6852-4568-B411-F6FBC4290EE6Q41976539-7FFF4834-A637-4C43-9B9A-C2B4DAFF9657
P2860
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Systemic candidiasis in cancer patients.
@en
Systemic candidiasis in cancer patients.
@nl
type
label
Systemic candidiasis in cancer patients.
@en
Systemic candidiasis in cancer patients.
@nl
prefLabel
Systemic candidiasis in cancer patients.
@en
Systemic candidiasis in cancer patients.
@nl
P2093
P1476
Systemic candidiasis in cancer patients.
@en
P2093
Fainstein V
Maksymiuk AW
Thongprasert S
P407
P577
1984-10-01T00:00:00Z